ArticleBlood advances2022

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.

Amy D Shapiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.